Nektar Therapeutics (NKTR) : 7 brokerage houses believe that Nektar Therapeutics (NKTR) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 7 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.
Nektar Therapeutics (NKTR) : The consensus price target for Nektar Therapeutics (NKTR) is $19 for the short term with a standard deviation of $3.79. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $25, however, the pessimist price target for the company is $14.
Shares of Nektar Therapeutics rose by 3.62% in the last five trading days and 18.62% for the last 4 weeks. Nektar Therapeutics is up 24.9% in the last 3-month period. Year-to-Date the stock performance stands at 7.77%. Nektar Therapeutics (NASDAQ:NKTR): stock turned positive on Tuesday. Though the stock opened at $17.8, the bulls momentum made the stock top out at $18.36 level for the day. The stock recorded a low of $17.79 and closed the trading day at $18.16, in the green by 1.85%. The total traded volume for the day was 1,243,716. The stock had closed at $17.83 in the previous days trading.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.